Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease - No Study Results Posted

Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease (LAR)

This study is currently recruiting participants.

Study NCT00690430 Information provided by Novartis

First Received: May 15, 2008 Last Updated: March 29, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	March 2015 (Final data collection date for primary outcome measure)